Cryoablation for Monomorphic Ventricular Tachycardia (VTS)
← catalyst calendarNCT07650032 · readout in 224 d
Sponsored by Adagio Medical (industry) · ADGM — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
10
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-01 | estimated | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ventricular Tachycardia, Sustained
- Ventricular Tachycardia, Monomorphic
Intervention
- Device: Ultra Low Temperature Ablation (ULTA)
Primary outcomes
what the primary-completion date above is the date OFPrimary Safety Endpoint - Freedom from definite or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure.
measured 7 days following the ablation procedure
Primary Efficacy Endpoint - Freedom from recurrent sustained MMVT in the absence of a new AAD or increase in dose of a pre-ablation AAD for VT management at 6 months following the ablation procedure
measured 6 months after the procedure
Primary Procedural Endpoint - Percentage of non-inducibility VT targeted for ablation post-procedure
measured at the end of the ablation procedure
Permalink · ADGM's whole pipeline · Catalyst calendar · Every registered study · What changed